BKYI — BIO-key International, Inc. Company Overview

Executive Summary

BIO-key International, Inc. (OTC: BKYI, formerly Nasdaq-listed) is a small identity and access management (IAM) company specializing in biometric multi-factor authentication (MFA) for passwordless, secure workforce access. The company's core differentiator is what it calls "Identity-Bound Biometrics" (IBB) — server-secured biometric authentication that does not require users to carry hardware tokens or phones, which BIO-key positions as superior to conventional MFA approaches reliant on possession factors. As of December 31, 2025, the company served more than 600 customers across government, education, healthcare, and financial-services verticals, generating approximately $6.1 million in total 2025 revenue. However, BIO-key is a financially distressed micro-cap: its auditor issued a going-concern qualification, the company was delisted from Nasdaq in May 2026 for failing both the $1.00 minimum bid price requirement and timely SEC reporting obligations, and it now trades over-the-counter with a market capitalization of roughly $5.7 million. Management has effected a 1-for-10 reverse stock split and is appealing for relisting, while projecting a path to profitability in the first half of 2026 on rising recurring revenue and cost reductions — claims that warrant significant skepticism given the company's history of losses and negative operating cash flow.

Core Business Model

BIO-key generates revenue by selling a combination of software (cloud-based identity platform subscriptions), hardware (biometric fingerprint scanners), and services to organizations seeking to replace or augment password-based authentication with biometric MFA and single sign-on (SSO). The company's model has shifted over recent years toward hardware: hardware products represented 22% of 2025 revenue, up sharply from 9% in 2024, indicating either a strategic pivot toward device sales or softness in the higher-margin software/subscription business — a trend that, absent further context, raises questions about the durability of BIO-key's SaaS/recurring revenue thesis.

Business Segments

BIO-key does not report formal multi-segment financials; its business is organized around a single integrated identity-and-access-management offering delivered through several product lines:

• PortalGuard / PortalGuard IDaaS — the company's flagship cloud-based identity platform, providing MFA, SSO, and self-service password reset for enterprise, education, and government customers.
• WEB-key — a biometric service management platform aimed at large-scale civil ID and government identity programs.
• MobileAuth — a mobile phone-based authentication application supporting iOS and Android, extending BIO-key's biometric factors to consumer mobile devices.
• Biometric Hardware — fingerprint scanners including the SidePass, EcoID II, and PIV-Pro product lines, sold both standalone and bundled with the software platform.

Product Portfolio

• PortalGuard IDaaS (cloud identity/MFA/SSO platform)
• WEB-key (civil ID/government biometric service management)
• MobileAuth (mobile biometric authentication app)
• SidePass, EcoID II, and PIV-Pro fingerprint scanners
• Seventeen distinct authentication factors offered across its IBB architecture

Competitive Landscape

BIO-key competes against significantly larger and better-capitalized identity and biometrics providers, including IDEMIA, Thales, and NEC, all of which have far greater scale, government relationships, and R&D budgets, as well as a broad field of general-purpose IAM suite vendors (e.g., Okta, Microsoft, Ping Identity-type competitors, though these were not specifically named in the filing) that bundle MFA into wider identity platforms. BIO-key's stated competitive positioning rests on its "unparalleled server-secured biometric authentication capability" across seventeen authentication factors — a narrow technical differentiation that has not translated into scale: at roughly $6.1 million in annual revenue, BIO-key is a rounding error relative to its named competitors, all of which serve the same government and enterprise identity markets with far deeper resources.

Strategic Strengths & Risks

Strengths: BIO-key's Identity-Bound Biometrics technology is a genuine technical differentiator in a market where most MFA solutions rely on possession-based tokens or phones; this appeals particularly to public-sector and civil-ID customers who need biometric verification without dependence on a user carrying a device. A base of over 600 customers across government, education, healthcare, and financial services provides some revenue diversification despite the small overall scale.

Risks: The risk profile here is severe and dominates the investment case. The auditor's going-concern qualification reflects a history of losses, limited cash, and negative operating cash flow, with the company disclosing a monthly operational cash requirement of approximately $750,000 against total annual revenue of only $6.1 million — an unsustainable burn rate without additional financing or a dramatic operational turnaround. The company was delisted from Nasdaq in May 2026 for failing the $1.00 minimum bid price requirement and for failing to timely file its 2025 Form 10-K, and now trades on the OTC market with reduced liquidity (average volume of roughly 34,000 shares) and diminished institutional visibility. A 1-for-10 reverse stock split (effective April 30, 2026) failed to cure the listing deficiencies in time, and while the company has appealed with a hearing in June 2026, relisting is not assured. Management's claim of a path to profitability in the first half of 2026 has not yet been substantiated by audited results and should be treated with caution given the company's operating history.

Financial Overview

BIO-key generated total revenue of approximately $6.1 million in 2025, with hardware sales rising to 22% of revenue (from 9% in 2024), suggesting a mix shift that may pressure overall gross margins given hardware's typically lower margin profile relative to software subscriptions. The company disclosed a monthly cash burn of roughly $750,000, which against its current market capitalization of about $5.7 million implies the company's entire equity value is smaller than roughly eight months of operating cash needs — a stark illustration of its financial fragility. The going-concern opinion from its independent auditor is a formal signal that continued operations are not assured absent additional capital raises, further cost cuts, or a strategic transaction.

Summary Conclusion

BIO-key International possesses a differentiated biometric authentication technology and a diversified small customer base, but it is best characterized as a distressed micro-cap rather than a viable growth story at this stage. Nasdaq delisting, a going-concern audit opinion, a cash burn rate that outpaces revenue, and intense competition from vastly larger identity-security players (IDEMIA, Thales, NEC) collectively point to a company facing existential financial risk. Any investment thesis here is speculative and contingent on successful capital raising, a Nasdaq relisting, and a credible path to the profitability management has projected for the first half of 2026.